BODYCOTE PLC (BOY) — Investment Research Note

Executive summary

Bodycote is the world's largest provider of heat treatment and specialist thermal processing services, operating ~130 sites in 22 countries serving aerospace & defence, automotive, energy, industrial, and medical end markets. Across the covered period the group navigated mixed cyclical markets and inflation to grow Core organic revenue modestly, executed a portfolio-improvement programme ("Optimise, Perform, Grow") that took Core adjusted operating margins from ~15% toward a stated >20% by 2028 target, and made strategic acquisitions in Specialist Technologies (Spectrum, Jan 2026). The single most important valuation fact today is that Veritas Capital has agreed a recommended cash offer at 940p per share (932.8p cash + 7.2p permitted FY26 interim dividend) 2026-09-01 Rule 2.7 Announcement; the shares trade at 948.5p, essentially at the deal price, and this is a merger-arb situation, not a fundamental equity investment.

Fair value estimate

• Fair value range: 935p – 970p per share (implied market cap ~£1,583m – £1,642m using 169.3m shares outstanding)
• Mid-point: 950p (£1,608m mcap)
• Methodology: Deal-driven merger arbitrage. The 940p Veritas offer, unanimously recommended by the board and supported by irrevocables from all directors, sets a hard floor for value assuming the deal closes (expected Q1 2027). Upside optionality (~30p) reflects the possibility of a bumped or competing bid — CVC ran a parallel process and reached 915p 2026-09-01. Apollo initially triggered the offer period in May 2026. A cross-check on standalone value (EV/EBITDA ~10x FY26E EBITDA of ~£195m implies EV ~£1,950m; less £220m net debt/leases/pensions ≈ £1,730m equity ≈ 1,020p, though the market disregarded this in favour of the deal terms — undisturbed price was 683p 2026-09-01).
• Current disclosed market cap: £1,606m; latest quoted price 948.5p
• Absolute upside: ~0.2% at the midpoint (marginally negative on completion, ~2% positive in a bump scenario, ~30% downside if deal breaks and shares revert to ~680p undisturbed).

Sector context

• Sector confirmation: Industrials / Industrial Goods and Services (ICB). Bodycote is a global asset-heavy processing services business — closer in profile to specialist industrial services than to a pure engineered products manufacturer.
• Quality vs peers: Above-average asset intensity but higher-than-typical margins and returns (FY25 headline operating margin 15.7%, ROCE 14.2%) reflecting scale advantages and accreditations (Nadcap, IATF 16949). Leverage is well below industrial peers at ~0.6x net debt/EBITDA.
• Listed peers: None are direct matches (Bodycote is uniquely the world's largest independent heat treater). Loose comparators include CoorsTek (private, ceramics/thermal), thyssenkrupp (industrial services division), and captive heat-treatment operations inside Precision Castparts (owned by Berkshire). Veritas' own portfolio companies Chromalloy and StandardAero are the closest strategic parallels.

Investment thesis (3 bullets)

1. Deal certainty at a full premium: The Veritas offer represents a 37.5% premium to the 3-month undisturbed VWAP and 42.5% to the 12-month VWAP 2026-09-01 Rule 2.7. The board unanimously recommends and has irrevocable undertakings; three of the world's largest PE firms (Apollo, CVC, Veritas) all valued the business in this range, providing strong triangulation on cash value.
2. Real but limited AI-adjacent exposure: Industrial Gas Turbines revenue was +11% in H1 2026 with growth "linked to data centres" 2026-07-28 Interim Results, and Specialist Technologies (Hot Isostatic Pressing, Surface Technology, S³P) serve semiconductor and aerospace supply chains that indirectly benefit from AI-driven capex. Aerospace & Defence organic growth reached +25% in H1 2026.
3. High operating leverage with strategic optionality: Specialist Technologies delivered 26.1% operating margins in H1 2026 on 16.7% organic growth 2026-07-28, demonstrating the drop-through profile. As a private company, Veritas can accelerate the Optimise programme (targeting £15m run-rate savings by mid-2027) and its telegraphed review of non-core Automotive/Industrial Precision Heat Treatment sites.

Key risks (3 bullets)

1. Deal-break risk (primary risk today): Requires 75% shareholder approval, court sanction, and multiple regulatory clearances across US (HSR, DDTC/ITAR), EU, UK (NSI Act), Germany, France, Sweden, Italy, Finland, Belgium, Netherlands, Denmark 2026-09-01 Appendix 1. Given the defence/aerospace exposure, US ITAR and UK NSI approvals are non-trivial. Break scenario implies ~30% downside to undisturbed 680p.
2. End-market cyclicality masked by deal: Automotive and Industrial markets remain "structurally challenged" per management, with continued Western European automotive weakness 2026-07-28. Absent the takeover, the shares would remain sensitive to a global industrial downturn.
3. Overpaying at current price: Buying at 948.5p locks in ~1% loss on deal completion (vs 940p offer value) with capped upside unless a bidder appears. This is inverted risk/reward for a fundamental investor.

Operating leverage

Bodycote is a classic high-fixed-cost, capacity-based industrial services business. The Group operates ~130 sites with 4,000 employees and significant plant/equipment (PPE £477.7m at Dec 2025). Employee costs (£268m in 2025) and utilities (£70m) dominate the cost base; incremental furnace hours drop through at high contribution margins. Specialist Technologies delivered 26.1% operating margins on £121m H1 2026 revenue 2026-07-28, and management explicitly targets Group headline operating margins of >20% by 2028 (vs 15.7% in 2025) — implying ~£25-30m incremental operating profit on modest revenue growth. A 10-20% revenue beat over plan would plausibly add 30-50% to operating profit given the fixed-cost structure and current spare capacity in Precision Heat Treatment. The Optimise programme (£15m run-rate savings by mid-2027) will further concentrate the fixed-cost base on higher-utilisation sites, amplifying leverage. This operating leverage is a key reason Veritas is buying — the value accrues to the private owner post-take-private.

Value-trap signals

• Structural challenge in Automotive/Industrial Precision Heat Treatment noted repeatedly 2026-09-01 background; 2026-07-28 H1 26; Non-Core segment being wound down implies ~£45m of FY24 revenue has been effectively written off as strategically unviable.
• Goodwill impairment of £18m in 2024 in NA AGI reflecting prolonged demand weakness 2024 Annual Report.
• ERP write-down of £28m in H1 2024 after failed operations module rollout — evidence of execution missteps 2024 H1 results.
• Otherwise: fortress balance sheet, 38-year dividend track record, clean cash conversion. Not a classic value trap — the low undisturbed multiple reflected cyclical concerns, which is precisely why PE has stepped in.

Earnings vs expectations

Across the covered filings, Bodycote's disclosure practice provides only limited explicit guidance-vs-consensus comparisons. However:

• H1 2026: "Performance in the first half was in line with our expectations" 2026-07-28; FY guidance unchanged.
• H1 2025: "In line with expectations… full year outlook in line with market expectations" 2025-07-30, referencing company-compiled consensus of £115.7-123.0m operating profit.
• May 2024 update: Trading in line, guidance maintained; Nov 2024 update: full-year expectations reiterated at £62.2m H2 2024 op profit.
• FY 2024 delivered adjusted operating profit of £129.0m (vs FY23 £127.6m), broadly in line.
• The Nov 2021 update flagged a ~£10m/1.6% revenue miss from automotive supply-chain issues — the only clear miss in the period.

Pattern: predominantly "in line" with occasional cyclical misses — not a serial beater, not a serial disappointer. Score ~55.

Conviction

Conviction: 5 (very high) — but conviction is on the deal-completion-driven fair value, not on standalone fundamentals.

Anchors: (1) Firm Rule 2.7 announcement with unanimous board recommendation and irrevocables from all directors; (2) Three PE firms independently valued in the 915-940p range, providing convergent triangulation; (3) Cash offer with committed financing from BofA, Deutsche Bank, UBS, Citi.

Limiters: (1) Regulatory approval risk across 13+ jurisdictions (particularly NSI/ITAR given defence content); (2) Small probability window for a bumped bid remains open.

Overall score rationale

At 948.5p vs a 940p cash offer, this is functionally a merger-arb situation, not a public equity investment. For an investor seeking AI-receiver exposure with operating leverage and valuation discipline, Bodycote fails all three tests: (a) the stock is being taken private in Q1 2027, so any AI/IGT upside accrues to Veritas, not shareholders; (b) at 948p the price is above the offer, providing no valuation discipline; (c) operating leverage cannot be captured by public holders. Even the "downside protection" argument is weak — a deal break implies ~30% loss. This is uninvestable for the stated strategy.